



FOR IMMEDIATE RELEASE

Anson Group Joins Navigant

Significantly Enhancing Firm's Life Sciences Expertise and Service Offerings

Tuesday, July 9, 2013

CHICAGO – July 9, 2013 – Navigant (NYSE: NCI) announced today that the professionals of Anson Group, a life sciences regulatory consulting firm focused on navigating the federal and global regulatory requirements of life sciences companies, have joined Navigant. The team of professionals brings significant expertise in the sector including the management of responses to regulatory enforcement, corrective action/remediation, regulatory compliance assessments and product submission strategies.

“The FDA regulatory compliance environment is experiencing increasing levels of government scrutiny and enforcement,” said Kevin Cornish, Managing Director and leader of Navigant’s Healthcare and Life Sciences Disputes, Compliance and Investigations practice. “The union of Anson Group and Navigant’s HLS DCI practice responds to the increasing demand by the Life Sciences industry for specialized support in responding to regulatory enforcement, developing remediation strategies and providing ongoing regulatory compliance services. The addition of this highly specialized and deeply experienced team of professionals allows Navigant to offer a more comprehensive set of compliance and FDA regulatory offerings to the Life Sciences industry.”

Founded in 1996, the Anson Group offered regulatory commercialization and compliance services for companies that develop and market medical products in the areas of Drugs and Biologics, Medical Devices, Combination Products, and Connected Health Technology. Its client list spans the life sciences sector and includes large pharmaceutical firms, specialty pharmaceutical companies, biotech firms and medical and diagnostic device companies.

“We are very excited about joining Navigant,” said Colleen Hittle, Managing Director with Navigant and previously Anson Group’s President and Chief Executive Officer. “Our deep expertise in FDA regulatory strategy and compliance expands the services Navigant delivers to its client base. Equally important, our clients and professionals will benefit from the broader life sciences capabilities resident at Navigant, and the potential of collaborating across the firm in pursuit of additional growth opportunities.”

No further details about the transaction were disclosed.

About Navigant Life Sciences Expertise

Navigant's Life Sciences experts assist global pharmaceutical, biotechnology, medical device, diagnostic, biomarkers and drug delivery companies in both an advisory as well as an event driven capacity. The Dispute, Compliance and Investigative professionals provide life sciences entities with compliance and risk mitigation services; dispute resolution and litigation support; government enforcement support; fraud and other special investigations. Navigant's advisory specialists provide expertise in strategic marketing, business insights, market access, brand management, and pricing and reimbursement initiatives. Navigant's team of industry experts includes healthcare executives, clinicians and commercial leaders who combine industry knowledge and deep regulatory experience, a global perspective and practical consulting experience to provide the right approach to the unique issues our clients face. More information about Navigant's Life Sciences expertise can be found at www.navigant.com/lifesciences.

About Navigant

Navigant (NYSE: NCI) is a specialized, global expert services firm dedicated to assisting clients in creating and protecting value in the face of critical business risks and opportunities. Through senior level engagement with clients, Navigant professionals combine technical expertise in Disputes and Investigations, Economics, Financial Advisory and Management Consulting, with business pragmatism in the highly regulated Construction, Energy, Financial Services and Healthcare industries to support clients in addressing their most critical business needs. More information about Navigant can be found at www.navigant.com.

For more information contact:

Laura Elias
Navigant Marketing
312.583.2694

Paul Longhini
Navigant Investor Relations
312.583.5836

###